Klein, Robert J. http://orcid.org/0000-0003-3539-5391
Vertosick, Emily http://orcid.org/0000-0001-6948-9850
Sjoberg, Dan
Ulmert, David
Rönn, Ann-Charlotte http://orcid.org/0000-0002-2493-3142
Häggström, Christel
Thysell, Elin
Hallmans, Göran
Dahlin, Anders
Stattin, Pär
Melander, Olle
Vickers, Andrew
Lilja, Hans http://orcid.org/0000-0001-5871-7846
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA175491, R01 CA244948, P30 CA008748, P50 CA92629)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (S10 OD018522, S10 OD026880)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Prostate Cancer Foundation
Cancerfonden (CAN 2017/559)
Vetenskapsrådet (2016-02974)
General Hospital in Malmö Foundation for Combating Cancer Sidney Kimmel Center for Prostate and Urologic Cancers
Article History
Received: 26 September 2021
Accepted: 11 February 2022
First Online: 8 April 2022
Competing interests
: H.L. is named on a patent for intact PSA assays. A.V. and H.L. are named on a patent for a statistical method to detect prostate cancer that has been licensed to and commercialized by OPKO Health. They both receive royalties from sales of the test. A.V. has stock options and H.L. has stock in OPKO Health. No other authors have any competing interests to declare.